Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DUVAC
- Development stage
- Unknown
- Lead developer
- Orgenesis
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules
- Administration
- Injection
01
Overview
DUVAC is a therapeutic cellular vaccine platform developed by Orgenesis in collaboration with Columbia University for the treatment of pancreatic cancer and other solid tumors, including hepatic and cholangiocarcinoma. The platform utilizes a patented dual-vaccine design that combines whole cancer cells as a comprehensive source of antigens with the patient's own autologous dendritic cells and macrophages. These antigen-presenting cells are used to activate a T-cell-mediated immune response against the tumor. The preparation protocol involves a specific combination of chemotherapy agents—dexamethasone, urea, vincristine, doxorubicin, and carmustine—which are likely used to process the tumor cells or modulate the immune environment to enhance antigenicity. The therapy is currently in Phase 1/2 clinical development.
- Other names
- Cellular vaccineTherapeutic cellular vaccine platformdexamethasone + urea + vincristine + doxorubicin + carmustine-Orgenesis-Cellular vaccine-cell therapy-Solid Tumors-Pancreatic Cancer
Beyond the preview
Go deeper on DUVAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DUVAC.